{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"OR was defined as the number of participants who achieved a best response of either CR or PR per the Lugano Classification. CR and PR per Lugano classification is defined in outcome measure #25.","groups":[{"description":"Participants with Relapsed/Refractory Burkitt Lymphoma received the following treatment during the study: Lymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG000","title":"Substudy C (Relapsed/Refractory Burkitt Lymphoma): Brexucabtagene Autoleucel"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants in substudy C, in the Modified Intent-to-Treat Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Substudy C: Number of Participants With OR Determined by Investigator Assessment Per the Lugano Classification","type":"SECONDARY","unitOfMeasure":"Participants"}